By Anoopa Singh | Wed, 06/12/2013 - 18:53
Mothers on life-saving medications are more and more likely to stop taking them for fear that the drugs increase the risk of birth defects in their children — now researchers are attempting to measure how necessary these drugs are.
By Nsikan Akpan | Fri, 05/10/2013 - 12:55
The FDA-approved inhaler is now available to treat the lung disease COPD.
By Cindy del Rosario | Sun, 04/28/2013 - 13:19
Proposed changes to Medicare and Medicaid will result in lower payments to hospitals with poor patient safety and hospitals that serve low-income patients.
By Justin Caba | Thu, 03/28/2013 - 14:56
The Center's for Disease Control and Prevention has launched its second anti-smoking campaign aimed at second hand smoking.
By Staff Reporter | Mon, 07/02/2012 - 17:19
GlaxoSmithKline's experimental once-daily lung drug LAMA/LABA showed positive results on Monday from late stage trials in patients with chronic obstructive pulmonary disease (COPD).
By James Heather | Thu, 07/28/2011 - 10:27
According to Australian researchers, cigarette smoke exposure permanently alters the cellular structure of the tissues in the airway from people with Chronic Obstructive Pulmonary Disease (COPD). Causing airway thickening and even causing precancerous cells to increase long after cigarette smoke exposures has ended.
By Staff Reporter | Thu, 05/26/2011 - 10:10
Patients with rheumatoid arthritis are two times more likely to have concurrent chronic obstructive pulmonary disease (COPD) than healthy controls -- an association which was sustained even when variables such as age, gender, smoking and obesity were controlled for, according to a study presented today at the EULAR 2011 Annual Congress.
By Staff Reporter | Mon, 05/16/2011 - 09:45
The six-minute walking distance test (6MWD), a test that measures a patient's ability to tolerate exercise and physical activity, is an effective tool for understanding disease severity in patients with chronic obstructive pulmonary disease (COPD), according to a three-year global study of patients with COPD sponsored by drug manufacturer GlaxoSmithKline.
By Staff Reporter | Mon, 04/18/2011 - 09:32
Michael Croft, Ph.D., a researcher at the La Jolla Institute for Allergy & Immunology, has discovered a molecule's previously unknown role as a major trigger for airway remodeling, which impairs lung function, making the molecule a promising therapeutic target for chronic asthma, chronic obstructive pulmonary disease (COPD) and several other lung conditions. A scientific paper on Dr. Croft's finding was published online today in the prestigious journal, Nature Medicine.